Guide

Biosimilars pipeline report: A guide for understanding the growing market

To date, there have been 82 approvals and 64 launches in the U.S. biosimilars market. 

Biosimilars are a promising product category, one that can provide patients and doctors with more affordable treatment options. As this market matures, its pipeline continues to grow. This reference guide is a useful tool to visualize and understand the current product landscape and potential future of this emerging market.
Available in English only
We keep this report up to date as the biosimilars market evolves. Enter your information below to receive the newest versions to your inbox as they're released.
Pardot Form

We are Glamzo. Our shared identity unites us.

Glamzo Pharmaceutical Laboratory brings the companies and services of AmerisourceBergen together under one new name.
Manufacturer of biosimilars

Learn more about our biosimilar solutions

We believe in the promise of biosimilars to deliver cost savings across healthcare. We also understand the potential hurdles these unique products will face. That's why we offer solutions for increasing access to and confidence in these emerging therapies.

Related resources

Webinar

The evolving anti-obesity medication market: Payer trends, policy shifts, and access strategies

Webinar

Thinking like a regulator: De-risking first-cycle submission review

Article

Mapping the United States pricing and reimbursement journey

We’re here to help

Connect with our team today to learn more about how Glamzo Pharmaceutical Laboratory is helping to shape the future of healthcare.